卡铂、复方苦参注射液序贯胸腔灌注联合静脉化疗治疗恶性胸腔积液的疗效观察  

Efficacy Observation of Carboplatin and Compound Matrine Injection Combined with Intravenous Chemotherapy in the Treatment of Malignant Pleural Effusion with Sequential Intrathoracic Perfusion

作　　者：温宏升[1] 杨芳[1] 李旭[1] 曹玉柱[1] 史昱旻 彭丽敏[1] 

机构地区：[1]宁波开发区中心医院肿瘤内科,浙江宁波315800

出　　处：《中国药房》2012年第40期3790-3792,共3页China Pharmacy

摘　　要：目的:观察卡铂、复方苦参注射液序贯胸腔灌注联合静脉化疗治疗恶性胸腔积液的疗效和不良反应。方法:72例恶性胸腔积液患者随机均分为2组。胸腔置管充分引流后,试验组给予卡铂400mg,d1;复方苦参注射液30mL,d4、d7,胸腔注射。对照组仅给予卡铂400mg,d1,胸腔注射。全部患者在卡铂胸腔灌注前给予相应单药标准剂量静脉化疗,化疗同时予以常规对症、支持治疗。3周为1个治疗周期,治疗1个周期胸腔积液未达完全缓解(CR)者,可重复1个治疗周期(最多用药2个周期)。治疗结束后观察疗效和不良反应。结果:试验组控制胸腔积液有效率为91.7%,显著高于对照组(66.7%),差异有统计学意义(P=0.009);试验组胸腔积液CR率(75.0%)也显著高于对照组(47.2%),差异有统计学意义(P=0.016)。2组患者不良反应可耐受,发生率差异无统计学意义(P>0.05)。结论:从疗效和不良反应两方面衡量,卡铂、复方苦参注射液序贯胸腔灌注联合静脉化疗是治疗恶性胸腔积液的较好选择。OBJECTIVE： To observe therapeutic efficacy and adverse drug reaction of sequential intrathoracic perfusion of car-boplatin and Compound matrine injection combined with intravenous chemotherapy in the treatment of malignant pleural effusion. METHODS： A total of 72 patients with malignant pleural effusion were randomly assigned into 2 groups. After chest catheterization adequate drainage, trial group received carboplatin 400 mg, d1, and Compound matrine injection 30 mL, d4, d7 intrapleurally. Control group was given carboplatin 400 mg d1 by intrathoracic perfusion. All patients were given intravenous chemotherapy of standard dose of single drug before intrathoracic perfusion of carboplatin. At the same time, they were given routine symptomatic support treatment. A treatment course lasted for 3 weeks. Another treatment cycle could be repeated if complete remission （CR） was not achieved after a treatment course （2 weeks of administration at the most）. The therapeutic efficacy and adverse drug reactions were observed after treatment. RESULTS： The effective rate of pleural effusion control in trial group was 91.7 % （33/36）, which was sig-nificantly higher than in control group （66.7%）, there was statistical significance（P=0.009） ;complete remission （CR） rate of trial group （75.0%） was also significantly higher than that of control group （47.2%）, there was statistical significance （P=0.016）. The adverse drug reactions （ADR） in 2 groups were tolerable, and there was no significant difference in incidence of ADR（P〉0.05）. CONCLUSION： From the respective of therapeutic efficacy and ADR, it is a better choice to treat malignant pleural effusion by in-travenous chemotherapy combined with sequential intrathoracic perfusion of carboplatin and Compound matrine injection.

关 键 词：卡铂 复方苦参注射液 恶性胸腔积液 序贯胸腔灌注 静脉化疗 疗效 不良反应 

分 类 号：R979[医药卫生—药品]